• 1.哈爾濱醫(yī)科大學(xué)附屬第一臨床醫(yī)院第三住院部普外科(哈爾濱150001);;
  • 2.哈爾濱醫(yī)科大學(xué)附屬第一臨床醫(yī)院普外科(哈爾濱150001);

目的　 探討抑癌基因 Lumican mRNA在胃癌組織中的表達(dá)及其在胃癌發(fā)生、發(fā)展中的意義。
方法 　采用逆轉(zhuǎn)錄聚合酶鏈反應(yīng)(RT-PCR)方法檢測66例胃癌組織及其相應(yīng)的近癌旁組織及正常組織中Lumican mRNA的表達(dá)，并分析胃癌組織中Lumican mRNA表達(dá)與其臨床病理特征的關(guān)系。
結(jié)果 　Lumican mRNA在胃癌組織、近癌旁組織及正常組織中的表達(dá)缺失率分別為42.4%(28/66)、15.2%(10/66)及0(0/66)。有淋巴結(jié)轉(zhuǎn)移者胃癌組織中Lumican mRNA表達(dá)缺失率(61.1%)明顯高于無淋巴結(jié)轉(zhuǎn)移者(20.0%)，差異有統(tǒng)計學(xué)意義(χ2=11.323,P=0.001); 晚期(Ⅲ、Ⅳ期)胃癌組織中Lumican mRNA表達(dá)缺失率(61.5%)明顯高于早期(Ⅰ、Ⅱ期，30.0%），差異有統(tǒng)計學(xué)意義(χ2=6.417,P=0.011; 胃癌組織中Lumican mRNA表達(dá)缺失與腫瘤分化程度無關(guān)(χ2=1.576,P=0.455)。
結(jié)論 　Lumican mRNA表達(dá)缺失可能在胃癌的發(fā)生和發(fā)展過程中起重要作用, 并影響其預(yù)后。

引用本文： 羅海蓉,劉連新,姜洪池. 抑癌基因Lumican在胃癌中的表達(dá)及其臨床意義. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(5): 551-553. doi: 復(fù)制

1. 　文亞淵， 劉寶華， 洪勝龍， 等. 凋亡相關(guān)基因survivin、 caspase-3及cyclin-B1在胃癌發(fā)生、 發(fā)展中的作用 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志， 2006； 13（1）∶34.
2. 　Chakravarti S, Stallings RL, SundarRaj N, et al. Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22 [Ｊ]. Genomics, 1995; 27(3)∶481.
3. 　Leygue E, Snell L, Dotzlaw H, et al. Expression of lumican in human breast carcinoma [Ｊ]. Cancer Res, 1998; 58(7)∶1348.
4. 　Koninger J, Giese T, di Mola FF, et al. Pancreatic tumor cells influence the composition of the extracellular matrix [Ｊ]. Biochem Biophys Res Commun, 2004; 322(3)∶943.
5. 　Lu YP, Ishiwata T, Kawahara K, et al. Expression of lumican in human colorectal cancer cells [Ｊ]. Pathol Int, 2002; 52(8)∶519.
6. 　Shinji S, Tajiri T, Ishiwata T, et al. Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma [Ｊ]. Int J Oncol, 2005; 26(4)∶873.
7. 　Naito Z, Ishiwata T, Kurban G, et al. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests [Ｊ]. Int J Oncol, 2002; 20(5)∶943.
8. 　Vij N, Roberts L, Joyce S, et al. Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea [Ｊ]. Exp Eye Res, 2004; 78(5)∶957.
  1. 1. 　文亞淵， 劉寶華， 洪勝龍， 等. 凋亡相關(guān)基因survivin、 caspase-3及cyclin-B1在胃癌發(fā)生、 發(fā)展中的作用 [Ｊ]. 中國普外基礎(chǔ)與臨床雜志， 2006； 13（1）∶34.
  2. 2. 　Chakravarti S, Stallings RL, SundarRaj N, et al. Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22 [Ｊ]. Genomics, 1995; 27(3)∶481.
  3. 3. 　Leygue E, Snell L, Dotzlaw H, et al. Expression of lumican in human breast carcinoma [Ｊ]. Cancer Res, 1998; 58(7)∶1348.
  4. 4. 　Koninger J, Giese T, di Mola FF, et al. Pancreatic tumor cells influence the composition of the extracellular matrix [Ｊ]. Biochem Biophys Res Commun, 2004; 322(3)∶943.
  5. 5. 　Lu YP, Ishiwata T, Kawahara K, et al. Expression of lumican in human colorectal cancer cells [Ｊ]. Pathol Int, 2002; 52(8)∶519.
  6. 6. 　Shinji S, Tajiri T, Ishiwata T, et al. Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma [Ｊ]. Int J Oncol, 2005; 26(4)∶873.
  7. 7. 　Naito Z, Ishiwata T, Kurban G, et al. Expression and accumulation of lumican protein in uterine cervical cancer cells at the periphery of cancer nests [Ｊ]. Int J Oncol, 2002; 20(5)∶943.
  8. 8. 　Vij N, Roberts L, Joyce S, et al. Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea [Ｊ]. Exp Eye Res, 2004; 78(5)∶957.